Melanie Hermreck

Statistics

Publications

Citations

484

H-Index

Active since

2018

Affiliations

Miragen Therapeutics (United States)(Current)

Melanie Hermreck is an author at Miragen Therapeutics (United States) specializing in microrna regulation in cancer, neoplasia, and molecular oncology.

Publications per year

2018–2021

Publications

Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma

Anita G. Seto, Xuan Beatty, Joshua M. Lynch et al. · British Journal of Haematology · 2018 · 315 citations · Full text

Medicine, Cancer Biology, Oncology +15

Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>

Eleni Anastasiadou, Anita G. Seto, Xuan Beatty et al. · Clinical Cancer Research · 2020 · 150 citations · Full text

Medicine, Oncology, Pharmacology +14

Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants

Peter A. Sieling, Thomas B. King, Raymond M.H. Wong et al. · medRxiv · 2021 · 19 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

1–3 of 3